Researchers have reported a potential oral treatment for Alzheimer’s disease that slowed its progression over a period of at least 18 months. Developed by Singaporean company TauRx Pharmaceutics Ltd, ...

Imatinib mesylate has anti-inflammatory properties, because it is a specific and potent inhibitor of several protein tyrosine kinases. Paniagua et al. have investigated imatinib's mechanism of ...

Officials are assessing whether hydromethylthionine mesylate (HMTM) shows sufficient promise to be given the green light for NHS patients. The drug attacks a protein called tau which accumulates ...